Medleyinc completes share buyback, plans flexible repurchase policy

Medleyinc announced the completion of its share repurchase program, which ran from September 1 to September 10, 2025. During this period, the company acquired 187,300 shares of its common stock through market transactions on the Tokyo Stock Exchange, totaling 457,377,200 yen. This buyback was executed under resolutions from board meetings on March 10, 2025, and August 15, 2025.

The concluded program was part of a broader resolution allowing for the repurchase of up to 1,050,000 shares, representing 3.3% of total outstanding shares (excluding treasury stock), and an aggregate amount of up to 3,000 million yen. This framework, extended to December 31, 2025, saw a cumulative acquisition of 1,050,000 shares for 2,848,746,500 yen as of September 10, 2025.

Medleyinc confirmed that while this specific phase of the buyback is complete, it will continue to consider future share repurchases flexibly as part of its capital policy, adapting to market conditions and the business environment.